ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma
CAR-T Therapies Will Beat T-Cell Engagers To Market
Executive Summary
Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.
You may also be interested in...
BMS Revenues Soar, But High-Flying Revlimid Is A Big Driver
The Celgene acquisition gave BMS a new top-selling drug but Revlimid revenue will start to decline as soon as next year and it is likely to take many new products to replace it.
Amgen Eschews Some Of Its BiTEs, But Otezla Spurs Growth
Without Otezla’s $2.2bn in 2020 sales, Amgen’s full-year revenue would have been slightly lower than in 2019, which is why all eyes are on the company’s R&D programs and near-term approvals.
Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports